Fjarde Ap-Fonden /Fourth Swedish National Pension Fund 13F: Cuts JNJ Stake by $40M

Fjarde Ap-Fonden /Fourth Swedish National Pension Fund reduced its stake in Johnson & Johnson (NYSE: JNJ) by 151,529 shares, a 12.1% decrease, according to its latest Form 13F filing on October 15, 2026. The fund now holds 1,105,140 shares valued at approximately $292.6 million.

What Changed in Fjarde Ap-Fonden's Johnson & Johnson Position

The fund's recent adjustment marks a notable shift in its investment strategy regarding Johnson & Johnson. The reduction reflects a strategic decision, as Fjarde Ap-Fonden had held 1,256,669 shares prior to this cut.

Other Institutional Activity in Johnson & Johnson

Several other institutional investors have been active with their Johnson & Johnson holdings. Blackrock Inc. reduced its position by 1,280,271 shares, ending with 212,098,264 shares worth about $54.2 billion. In contrast, Vanguard Capital Management LLC added 626,400 shares for a total of 157,226,374 shares valued at $40.2 billion. State Street Corporation also increased its stake by 293,661 shares to a total of 133,776,025 shares valued at $34.2 billion.

Johnson & Johnson Stock Up 0.5%

Johnson & Johnson shares recently traded around $255.22, which is approximately 3.8% below its 50-day moving average of $265.26. The stock is currently about 9.2% below its 52-week high of $281.07. However, it remains more than 38% above its 52-week low of $184.66. The mean price target from analysts is $279.41, suggesting the stock is still expected to perform better.

Recent Earnings

In its last earnings report, Johnson & Johnson reported a trailing twelve months revenue of $99.3 billion, along with an EPS of $6.59. The company experienced revenue growth of 5.9% year-over-year. Its next earnings date is set for January 26, 2027.

Insider Buying and Selling at Johnson & Johnson

Several insiders sold shares recently. On August 6, Officer Elizabeth Forminard sold 15,918 shares valued at about $4.1 million. CEO Joaquin Boix Duato sold 123,291 shares worth approximately $32.2 million on August 13. Jennifer L. Taubert, also an officer, sold 15,000 shares for about $3.95 million on August 17. Lastly, Officer Timothy Schmid sold 33,597 shares at an average price of $274.74, totaling approximately $9.2 million on September 2.

Analysts Set New Price Targets

On October 15, 2026, Morgan Stanley maintained its 'Overweight' rating on Johnson & Johnson with a price target of $292. This followed similar actions from Wells Fargo, which also kept its 'Overweight' rating but adjusted the target to $275. Other analysts, including Guggenheim and Leerink Partners, affirmed their positive outlook with price targets of $287 and $272, respectively.

About Johnson & Johnson

Johnson & Johnson is a leading healthcare company based in New Brunswick, NJ. It specializes in a wide range of healthcare products, operating mainly in two segments: Innovative Medicine and MedTech. This recent stake reduction by Fjarde Ap-Fonden may reflect broader market strategies or changing views on the healthcare sector overall.

Bottom Line

Investors should watch for Johnson & Johnson's upcoming earnings report on January 26, 2027, as the company continues to navigate its growth strategy. Fjarde Ap-Fonden's filing reflects its position as of the report date and may not represent its current holdings.